Evaluating a smart home system for patients with interstitial lung disease

Evaluation of the Effectiveness, Safety, and Cost of a Smart Home-based Hospital System for Patients With Interstitial Lung Disease: Prospective Multicenter Randomized Controlled Trial

This study is testing whether a smart home system can help people with interstitial lung disease manage their health better and save on healthcare costs.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 110 (estimated)
• Ages: 60 Years and up
• Sex: All
• Sponsor: Yonsei University (Academic / other)
• Locations: 1 site (Seoul)
• Trial ID: NCT06601790 on ClinicalTrials.gov

What this trial studies

This study analyzes the effectiveness, safety, and cost of the Smart Homespital system, which allows patients with interstitial lung disease to access and utilize biosignals generated by medical equipment at home. Participants will be randomly assigned to either immediate or delayed application of the system to assess its impact on their health outcomes. The study aims to provide insights into how home-based monitoring can improve patient care and reduce healthcare costs.

Who should consider this trial

Good fit: Ideal candidates include patients diagnosed with interstitial lung disease who have specific pulmonary function test results indicating moderate to severe impairment.

Not a fit: Patients who are bedridden, unable to communicate verbally, or currently receiving hospital-centered rehabilitation may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could enhance the management of interstitial lung disease, leading to better patient outcomes and reduced hospital visits.

How similar studies have performed: Other studies have shown promise in using home-based monitoring systems for chronic respiratory conditions, suggesting potential success for this approach.

Eligibility criteria

Inclusion Criteria:

Patients diagnosed with COPD who meet the following pulmonary function test results:

1. Pre FEV1 \< 80% \*\*or\*\*
2. Pre FVC \< 80% \*\*or\*\*
3. DLCO \< 60%

Exclusion Criteria:

1. Patients who do not agree to participate in the study.
2. Patients who fail to use the medical device equipment.
3. Patients where tracking during the study period is expected to be impossible.
4. Patients who have difficulty communicating verbally.
5. Patients who are bedridden or unable to exercise at all due to severe cardiorespiratory dysfunction.
6. Patients receiving hospital-centered rehabilitation treatment during the study period.

Where this trial is running

Seoul

• Division of Pulmonary and Critical Care Medicine — Seoul, South Korea (Recruiting)

Study contacts

• Study coordinator: Mindong Sung, PhD

Conditions Interstitial Lung Disease